Cablivi

PreclinicalSmall molecule

Cablivi is one of 5 small molecule programs targeting Thrombotic Thrombocytopenic Purpura. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thrombotic Thrombocytopenic PurpuraActive, not recruiting

Thrombotic Thrombocytopenic PurpuraPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Thrombotic Thrombocytopenic Purpura

#DrugCompanyPhaseTrials

Bayer Aspirin

Medrol

Vyvgart

1 4

TAK-755

Takeda

Phase 3

4 5

Cablivi

UUniversity of Cologne

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2034

Recruiting

Treatment

NCT04985318

Clinical

Trials by Indication[1]

Thrombotic Thrombocytopenic Purpura1 trial

Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

Completed·UUniversity of Cologne··NCT05876221·223 enrolled

Treatment1 trial

Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP

Recruiting·UUniversity of Cologne··NCT04985318·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cablivi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cablivi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cablivi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Cologne company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Cologne

Cablivi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2034

Trials by Indication[1]

Thrombotic Thrombocytopenic Purpura1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News